Assessing radiation dose for postoperative radiotherapy in prostate cancer: Real world data

Table 1 Clinicopathologic characteristics of the patients according to the radiotherapy dose to the surgical bed

	Total dose			P value
	66-68 Gy	70 Gy	72 Gy
Variable	n (%)
Patients, n (%)	59 (21.1)	131 (50)	89 (31.9)
Median age, range	63.3 (50-74)	62.7 (48-75)	62.3 (41-75)
PSA preRT				0.36
≤ 0.4 ng/mL	26 (44.1%)	59 (48.8%)	49 (55.7%)
>0.4 ng/mL	33 (55.9%)	62 (51.2%)	39 (44.3%)
cT stage				0.43
cT1	38 (67.9%)	65 (57%)	53 (66.2%)
cT2	18 (32.1%)	46 (40.4%)	26 (32.5%)
cT3	0 (0%)	3 (2.6%)	1 (1.2%)
pT stage				0
pT1-T2	45 (80.4%)	94 (75.2%)	41 (47.1%)
pT3-T4	11 (19.6%)	31 (24.8%)	46 (52.9%)
pN stage				0.32
N0	25 (42.4%)	60 (46.9%)	42 (48.3%)
N1	1 (1.7%)	5 (3.9%)	1 (1.1%)
Nx	33 (55.9%)	63 (49.2%)	44 (50.6%)
GS (biopsy)				0.06
≤ 6	31 (53.4%)	67 (52.8%)	32 (37.6%)
7	25 (43.1%)	53 (41.7%)	42 (49.4%)
≥ 8	2 (3.4%)	7 (5.5%)	11 (12.9%)
GS (prostatectomy)				0.01
≤ 6	7 (17.9%)	28 (29.5%)	9 (12.2%)
7	27 (69.2%)	49 (51.6%)	41 (55.4%)
≥ 8	5 (12.8%)	18 (18.9%)	24 (32.4%)
Margin status				0.81
Positive	33 (55.9%)	74 (56.9%)	54 (60.7%)
Negative	26 (44.1%)	56 (43.1%)	35 (39.3%)
Hormonotherapy				0
Yes	28 (48.3%)	50 (40.3%)	15 (18.1%)
No	30 (51.7%)	74 (59.7%)	68 (81.9%)
RT indication				0.68
Adjuvant RT	19 (32.2%)	41 (31.5%)	33 (37.1%)
Salvage RT	40 (67.8%)	90 (68.5%)	56 (62.9%)

GS: Gleason score; preRT: Pre-radiotherapy; PSA: Prostate-specific antigen